Update on systemic therapy of advanced non-small-cell lung cancer

Expert Review of Anticancer Therapy

Volumn 14, Issue 10, 2014, Pages 1189-1203

  Cufer, Tanja ^a   Knez, Lea ^a  

^a UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

Author keywords

advanced disease; non oncogene directed therapies; non small cell lung cancer; oncogene directed therapies; systemic therapies

Indexed keywords

AFATINIB; ALECTINIB; AZD 9291; BEVACIZUMAB; BEVACIZUMAB PLUS CARBOPLATIN PLUS PACLITAXEL; CARBOPLATIN; CARBOPLATIN PLUS PACLITAXEL; CERITINIB; CETUXIMAB; CISPLATIN; CISPLATIN PLUS GEMCITABINE; CISPLATIN PLUS PEMETREXED; CRIZOTINIB; DOCETAXEL; ERLOTINIB; GANETESPIB; GEFITINIB; GEMCITABINE; HM 61713; LUMINESPIB; NAVELBINE; NINTEDANIB; ONARTUZUMAB; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; RETASPIMYCIN; ROCILETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADENOCARCINOMA; ADVANCED CANCER; ALK GENE; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; EGFR GENE; ENZYME INHIBITION; GENE MUTATION; GENE REARRANGEMENT; HISTOLOGY; HUMAN; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; STANDARDIZATION; SYSTEMIC THERAPY; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; ONCOGENE; PATHOLOGY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; ONCOGENES; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84907553976     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.940327     Document Type: Review

References (144)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer. 2013. Available from: Http://globocan.iarc.fr [Last accessed 22 April 2014]
2. Žakelj MP, Žagar T, Zadnik V. Lung cancer in Slovenia. Endosc Rev 2008; 13(29):1218-25
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8
4. Cufer T, Ovcaricek T, O'Brien MER. Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years. Eur J Cancer 2013;49(6):1216-25
5. Li T, Kung H-J, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies. J Clin Oncol 2013;31(8):1039-49
6. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12(2):175-80
7. Cufer T, Vrdoljak E, Gaafar R, et al. Phase II, open-label, randomized study (SIGN) of single-Agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs 2006;17:401-9
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
9. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21(12):2237-46
10. Shepherd F, Douillard J, Fukuoka M, et al. Comparison of gefitinib and docetaxel in patients with pretreated advanced non-small-cell lung cancer (NSCLC): Meta-Analysis from four clinical trials. J Clin Oncol 2009;27(15 Suppl):Abstract 8011
11. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101(36):13306-11
12. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21): 2129-39
13. Clark GM, Zborowski DM, Santabárbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Clin Lung Cancer 2006;7(6):389-94
14. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008; 372(9652):1809-18
15. Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013;31(8):1070-80
16. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
17. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362(25):2380-8
18. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11(2):121-8
19. Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8):735-42
20. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(3): 239-46
21. Sequist L V, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31(27): 3327-34
22. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol 2014;15(2):213-22
23. Mitsudomi T, Morita S, Yatabe Y, et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor. J Clin Oncol 2012; 30(Suppl):Abstract 7521
24. Zhou C, Wu Y, Liu X, et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30(Suppl):Abstract 7520
25. Yang JCH, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31(27): 3342-50
26. Yang JC, Sequist L, Schuler M, et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/ L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUXLung 3). J Clin Oncol 2014;32(5 Suppl): Abstract 8004
27. Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial. J Clin Oncol 2012;30(24):3002-11
28. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004;22(5):777-84
29. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22(5):785-94
30. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25(12):1545-52
31. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23(25):5892-9
32. Reck M. Beyond the TRIBUTE trial: Integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. Future Oncol 2006;2(1):47-51
33. Wu Y-L, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial. Lancet Oncol 2013;14(8):777-86
34. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT02001896
35. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-6
36. Camidge DR, Bang Y-J, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 2012;13(10): 1011-19
37. Kim DW, Ahn MJ, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30(Suppl):Abstract 7533
38. Shaw AT, Kim D-W, Mehra R, et al. Ceritinib in ALK -rearranged non-small-cell lung cancer. N Engl J Med 2014;370(13): 1189-97
39. Kim D, Mehra R, Tan D, et al. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. J Clin Oncol 2014; 32(5 Suppl):Abstract 8003
40. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368(25):2385-94
41. Mok T, Kim D, Wu Y, et al. First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): Results of a phase III study (PROFILE 1014). J Clin Oncol 2014;32(5 Suppl):Abstract 8002
42. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 2013;18(7):865-75
43. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT00585195
44. Shaw AT, Engelman JA. ALK in lung cancer: Past, present, and future. J Clin Oncol 2013;31(8):1105-11
45. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501(7467):338-45
46. Majem M, Pallarès C. An update on molecularly targeted therapies in secondand third-line treatment in non-small cell lung cancer: Focus on EGFR inhibitors and anti-Angiogenic agents. Clin Transl Oncol 2013;15(5):343-57
47. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol 2012;13(5):528-38
48. Janne P, Ramalingam S, Yang J, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(5 Suppl):Abstract 8009
49. Sequist L, Soria J, Gadgeel S, et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 2014; 32(5 Suppl):Abstract 8010
50. Ranson M, Pao W, Kim D, et al. Preliminary results from a Phase I study with AZD9291: An irreversible inhibitor of epidermal growth factor receptor (EGFR) activating and resistance mutations in non-small-cell lung cancer (NSCLC). Eur J Cancer 2013;49(Suppl 3):S15
51. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT02094261
52. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01449461
53. Clinicaltrials.gov. Available from: Www. clinicaltrials.gov/show/NCT02094573
54. Janjigian YY, Smit EF, Horn L, et al. Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors. Ann Oncol 2012;23(Suppl 9):ix400-46. Abstract 12270
55. Spigel D, Edelman M, O'Byrne K, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 2014;32(5 Suppl):Abstract 8000
56. Kato T, Seto T, Nishio M, et al. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. J Clin Oncol 2014;32(5 Suppl):Abstract 8005
57. Ou SHI, Jänne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014;25(2):415-22
58. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01828099
59. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01828112
60. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT02075840
61. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01562015
62. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01579994
63. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01228435
64. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01752400
65. Schuler M, Yang C, Park K, et al. Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progress. J Clin Oncol 2014; 32(5 Suppl):Abstract 8019
66. Chaft JE, Oxnard GR, Sima CS, et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design. Clin Cancer Res 2011;17(19):6298-303
67. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01544179
68. Weickhardt AJ, Scheier B, Burke J, et al. Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30(Suppl):Abstract 7526
69. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-Analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26(28):4617-25
70. Delbaldo C, Michiels S, Rolland E, et al. WITHDRAWN: Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev 2012;4: CD004569
71. De Castria TB, da Silva EMK, Gois AFT, Riera R. Cisplatin versus carboplatin in combination with third-generation Drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev 2012;8: CD009256
72. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51
73. Roth JA, Carlson JJ. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: A systematic review and meta-Analysis. Clin Lung Cancer 2011; 12(6):393-401
74. Friboulet L, Olaussen KA, Pignon JP, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 2013;368(12):1101-10
75. Des Guetz G, Uzzan B, Nicolas P, et al. Comparison of the efficacy and safety of single-Agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-Analysis. Crit Rev Oncol Hematol 2012;84(3):340-9
76. Qi WX, Tang L, He A, et al. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: A systematic review and meta-Analysis. Lung 2012; 190(5):477-85
77. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011;378(9796):1079-88
78. Clinicaltrials.gov. Available from: Www. clinicaltrials.gov/ct2/show/NCT00401492
79. Clinicaltrials.gov. Available from: Http:// clinicaltrial.gov/ct2/show/NCT01405586
80. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-Analysis of randomized trials. J Clin Oncol 2009; 27(20):3277-83
81. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27(4):591-8
82. Belani C, Waterhouse D, Ghazal H, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (GCb) for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15 Suppl):Abstract 7506
83. Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005;97(7):499-506
84. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 2006;52(2): 155-63
85. Pérol M, Chouaid C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012;30(28):3516-24
86. Barlesi F, de Castro J, Dvornichenko V, et al. AVAPERL (MO22089): Final efficacy outcomes for patients (pts) with advanced non-squamous non-small cell lung cancer (nsNSCLC) randomised to continuation maintenance (mtc) with bevacizumab (bev) or bev + pemetrexed (pern) after first-line (1L) bev-cisplatin. Eur J Cancer 2011; 47(Suppl):16
87. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009;374(9699): 1432-40
88. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, random. Lancet Oncol 2012;13(3):247-55
89. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
90. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21(9):1804-9
91. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01351415
92. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(11):1835-42
93. Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/ cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012;30(25):3084-92
94. Lee JS, Hirsh V, Park K, et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012;30(10): 1114-21
95. Scagliotti G V, Vynnychenko I, Park K, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/ paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 2012;30(23): 2829-36
96. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUMELung 1): A phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15(2):143-55
97. Perol M, Ciuleanu T, Arrieta O, et al. REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior pl. J Clin Oncol 2014;32(5 Suppl):Abstract 8006
98. Patel JD, Socinski MA, Garon EB, et al. PointBreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB. J Clin Oncol 2013; 31(34):4349-57
99. Zinner R, Ross H, Weaver R, et al. Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell. J Clin Oncol 2013; 31(Suppl):Abstract LBA8003
100. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01107626
101. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009;373(9674):1525-31
102. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010;28(6):911-17
103. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: A retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011;12(8):795-805
104. Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(6):918-27
105. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13(1):33-42
106. Paz-Ares L, Mezger J, Ciuleanu T, et al. Randomized phase-3 trial (INSPIRE) of necitumumab plus cisplatin-pemetrexed versus cisplatin-pemetrexed alone as first-line therapy in stage IV non-squamous NSCLC. J Thorac Oncol 2013;8(Suppl 2):S139, Abstract O03.02
107. Thatcher N, Hirsch F, Szczesna A, et al. A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSC). J Clin Oncol 2014; 32(5 Suppl):Abstract 8008
108. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013;15(4):415.53
109. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: A review of two Phase III studies. Oncologist 2009; 14(3):253-63
110. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003;21(15): 2933-9
111. Rittmeyer A, Scherpereel A, Gorbunova V, et al. Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial. J Clin Oncol 2013;31(Suppl):Abstract 8014
112. Thomas F, Desmedt C, Aftimos P, Awada A. Impact of tumor sequencing on the use of anticancer drugs. Curr Opin Oncol 2014;26(3):347-56
113. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT00004883
114. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT00016367
115. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT00758134
116. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT00003881
117. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01336634
118. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01501604
119. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT00974584
120. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT00756847
121. Mazières J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013;31(16): 1997-2003
122. Planchard D, Mazieres J, Riely G, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2013;31(Suppl):Abstract 8009
123. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT00633789
124. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01491633
125. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01514864
126. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/ct2/show/NCT01310036
127. Brahmer JR. Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 2013;31(8):1021-8
128. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT00676507
129. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01015443
130. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT02049151
131. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01383148
132. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363(8):733-42
133. Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid. subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012;7(12): 1823-9
134. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01285609
135. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01642004
136. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01673867
137. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT02041533
138. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/ct2/show/NCT01905657
139. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/ct2/show/NCT02039674
140. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT02087423
141. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT02008227
142. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT02031458
143. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01846416
144. Clinicaltrials.gov. Available from: Http:// clinicaltrials.gov/show/NCT01774578